C WorldWide Group Holding A S Purchases 19,021 Shares of Insmed, Inc. (INSM)
C WorldWide Group Holding A S boosted its position in Insmed, Inc. (NASDAQ:INSM) by 15.5% during the second quarter, Holdings Channel reports. The institutional investor owned 141,471 shares of the biopharmaceutical company’s stock after buying an additional 19,021 shares during the period. C WorldWide Group Holding A S’s holdings in Insmed were worth $2,428,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in INSM. Driehaus Capital Management LLC purchased a new position in shares of Insmed during the first quarter worth approximately $192,000. Russell Investments Group Ltd. purchased a new position in shares of Insmed during the fourth quarter worth approximately $242,000. Parametric Portfolio Associates LLC increased its position in shares of Insmed by 39.2% in the first quarter. Parametric Portfolio Associates LLC now owns 14,417 shares of the biopharmaceutical company’s stock worth $252,000 after buying an additional 4,063 shares in the last quarter. Moody Aldrich Partners LLC increased its position in shares of Insmed by 37.7% in the second quarter. Moody Aldrich Partners LLC now owns 21,410 shares of the biopharmaceutical company’s stock worth $367,000 after buying an additional 5,860 shares in the last quarter. Finally, Highbridge Capital Management LLC increased its position in shares of Insmed by 250.1% in the fourth quarter. Highbridge Capital Management LLC now owns 36,930 shares of the biopharmaceutical company’s stock worth $489,000 after buying an additional 26,381 shares in the last quarter. Institutional investors and hedge funds own 92.69% of the company’s stock.
Shares of Insmed, Inc. (INSM) opened at 11.61 on Friday. The stock’s 50 day moving average price is $16.23 and its 200-day moving average price is $16.36. The stock’s market cap is $724.20 million. Insmed, Inc. has a 52 week low of $10.21 and a 52 week high of $19.35.
Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.09. Equities analysts anticipate that Insmed, Inc. will post ($2.70) earnings per share for the current fiscal year.
A number of equities analysts have commented on INSM shares. Zacks Investment Research upgraded shares of Insmed from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a report on Wednesday, July 5th. HC Wainwright restated a “buy” rating on shares of Insmed in a research note on Wednesday, August 2nd. Stifel Nicolaus boosted their price target on Insmed from $23.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, May 1st. ValuEngine upgraded Insmed from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, BidaskClub upgraded Insmed from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $22.00.
In other Insmed news, General Counsel Christine A. Pellizzari bought 10,000 shares of the business’s stock in a transaction dated Wednesday, May 31st. The shares were acquired at an average price of $15.14 per share, with a total value of $151,400.00. Following the transaction, the general counsel now owns 27,300 shares of the company’s stock, valued at $413,322. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 4.03% of the stock is currently owned by company insiders.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM).
Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.